Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS)
September 2, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS)  - JCN Newswire
Share:
Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS)

Tokyo, Mar 25, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that, at a meeting of its Board of Directors held earlier today, it resolved to voluntarily adopt International Financial Reporting Standards (IFRS) for consolidated financial statements in lieu of the Japanese Generally Accepted Accounting Principles (J-GAAP) it has currently adopted. Disclosure of consolidated financial statements under IFRS is scheduled to be implemented across the Eisai Group starting from the first quarter of the fiscal year ending March 31, 2015.

In line with its human health care (hhc) philosophy, the Eisai Group continues to conduct its pharmaceuticals business operations in diverse markets and regions, including Japan, the Americas, Europe and Asia. In this light, Eisai has resolved to voluntarily adopt IFRS across the Eisai Group to enable readier comparison and disclosure of financial information on an international basis and thereby increase convenience to various shareholders, investors and other stakeholders both in Japan and abroad.

The disclosure schedule for the Eisai Group's transition to IFRS is as follows (tentative):

May 2014: Financial results and consolidated financial statements for fiscal year ending March 31, 2014, under J-GAAP(1)
June 2014: Annual financial report for fiscal year ending March 31, 2014, under J-GAAP
August 2014: Financial results for first quarter of fiscal year ending March 31, 2015, under IFRS(2)
August 2014: Quarterly report for first quarter of fiscal year ending March 31, 2015, under IFRS(2)

Note:

(1) Consolidated forecasts for fiscal year ending March 31, 2015, to be disclosed under IFRS with provisional figures for fiscal year ending March 31, 2014, included for reference purposes
(2) Includes consolidated financial statements for fiscal year ending March 31, 2014

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

 


Mar 25, 2014
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Corporate Filings
View more news from these Sectors: Medical, Drugs & OTC, Biotech


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)